» Articles » PMID: 31672904

Platelet-derived Growth Factor Receptor β Activation and Regulation in Murine Myelofibrosis

Overview
Journal Haematologica
Specialty Hematology
Date 2019 Nov 2
PMID 31672904
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

There is prevailing evidence to suggest a decisive role for platelet-derived growth factors (PDGF) and their receptors in primary myelofibrosis. While PDGF receptor β (PDGFRβ) expression is increased in bone marrow stromal cells of patients correlating with the grade of myelofibrosis, knowledge on the precise role of PDGFRβ signaling in myelofibrosis is sparse. Using the Gata-1 mouse model for myelofibrosis, we applied RNA sequencing, protein expression analyses, multispectral imaging and, as a novel approach in bone marrow tissue, an proximity ligation assay to provide a detailed characterization of PDGFRβ signaling and regulation during development of myelofibrosis. We observed an increase in PDGFRβ and PDGF-B protein expression in overt fibrotic bone marrow, along with an increase in PDGFRβ-PDGF-B interaction, analyzed by proximity ligation assay. However, PDGFRβ tyrosine phosphorylation levels were not increased. We therefore focused on regulation of PDGFRβ by protein tyrosine phosphatases as endogenous PDGFRβ antagonists. Gene expression analyses showed distinct expression dynamics among PDGFRβ-targeting phosphatases. In particular, we observed enhanced T-cell protein tyrosine phosphatase protein expression and PDGFRβ-T-cell protein tyrosine phosphatase interaction in early and overt fibrotic bone marrow of Gata-1 mice. , T-cell protein tyrosine phosphatase () knockdown increased PDGFRβ phosphorylation at Y and Y, leading to enhanced downstream signaling in fibroblasts. Furthermore, knockdown cells showed increased growth rates when exposed to low-serum growth medium. Taken together, PDGF signaling is differentially regulated during myelofibrosis. Protein tyrosine phosphatases, which have so far not been examined during disease progression, are novel and hitherto unrecognized components in myelofibrosis.

Citing Articles

A Procedural Overview of the Involvement of Small Molecules in the Nervous System in the Regulation of Bone Healing.

Wei X, Li M, You J, Luo J, Zhai J, Zhang J Int J Nanomedicine. 2025; 20:1263-1284.

PMID: 39906525 PMC: 11792627. DOI: 10.2147/IJN.S505677.


CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation.

Huang M, Ke Z, Lyu M, Masarova L, Sadeghi T, Flowers C iScience. 2024; 27(9):110830.

PMID: 39314243 PMC: 11418154. DOI: 10.1016/j.isci.2024.110830.


PTPN14 aggravates neointimal hyperplasia via boosting PDGFRβ signaling in smooth muscle cells.

Ma Q, He X, Wang X, Zhao G, Zhang Y, Su C Nat Commun. 2024; 15(1):7398.

PMID: 39191789 PMC: 11350182. DOI: 10.1038/s41467-024-51881-x.


Exploring the molecular mechanisms between lymphoma and myelofibrosis.

Wang J, Li Y Am J Transl Res. 2024; 16(3):730-737.

PMID: 38586105 PMC: 10994807. DOI: 10.62347/NWJO7078.


Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

Verma T, Papadantonakis N, Peker Barclift D, Zhang L Cancers (Basel). 2024; 16(3).

PMID: 38339265 PMC: 10854658. DOI: 10.3390/cancers16030514.


References
1.
Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

2.
Wickenhauser C, Hillienhof A, Jungheim K, Lorenzen J, Ruskowski H, Hansmann M . Detection and quantification of transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF) release by normal human megakaryocytes. Leukemia. 1995; 9(2):310-5. View

3.
Wiede F, La Gruta N, Tiganis T . PTPN2 attenuates T-cell lymphopenia-induced proliferation. Nat Commun. 2014; 5:3073. DOI: 10.1038/ncomms4073. View

4.
Martinez-Calle N, Pascual M, Ordonez R, Eneriz E, Kulis M, Miranda E . Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and as a potential tumor suppressor gene that is epigenetically regulated. Haematologica. 2019; 104(8):1572-1579. PMC: 6669145. DOI: 10.3324/haematol.2018.204917. View

5.
Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L . JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015; 5(3):316-31. PMC: 4355105. DOI: 10.1158/2159-8290.CD-14-0736. View